Supplementary Materials

This PDF file includes:

  • Fig. S1. Increase in PTPN11 activity is TNK2 kinase–dependent.
  • Fig. S2. TNK2 inhibition reduces signaling through RAS/MAPK in 293T17 lysates.
  • Fig. S3. PTPN11 inhibition by SHP099 increases phospho-Tyr284 TNK2 and phospho-Tyr580 PTPN11.
  • Fig. S4. Mouse bone marrow colony formation assays with TNK2-specific inhibitors.
  • Fig. S5. Signaling effects of PTPN11 S502P mimic those seen with other PTPN11-activating mutations.
  • Fig. S6. Relative mRNA expression of dasatinib targets in AML patient samples from Fig. 5A.
  • Table S1. Inhibitor IC50 values in the JMML patient sample.
  • Table S2. siRNA panel data from the JMML patient sample.
  • Table S3. Mutations identified in PTPN11-mutant patient samples from Fig. 5A.
  • Table S4. Kd (dissociation constant) values of top dasatinib targets.

[Download PDF]